Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04749667
Other study ID # 159326
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date August 9, 2021
Est. completion date January 4, 2025

Study information

Verified date September 2023
Source Haukeland University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the study is to investigate neuroregenerative efficacy (proof of concept) of intrathecal treatment with autologous MSCs as measured by neurophysiological parameters in patients with progressive MS. Secondary objectives are to assess neuroregenerative efficacy as measured by other neurophysiological parameters as well as clinical, opthalmological and MRI modalities, and to assess safety of the treatment procedure.


Description:

Prospective, interventional, randomized, placebo-controlled, cross-over study. Patients are randomized to either treatment arm A or B. Patients in both treatment arms receive intrathecal autologous MSCs, arm A at baseline and arm B at six months. All patients undergo bone marrow (BM) aspiration prior to baseline. Patients in treatment arm A receive intrathecal autologous MSCs whereas patients in treatment arm B receive placebo. The treatment is blinded for the patients. The BM aspirate from patients in treatment arm B is processed, cryopreserved and stored in a biobank. At six months, all patients undergo a second BM aspiration. Patients in treatment arm A now receive placebo. The BM aspirate from patients in treatment arm A is processed, cryopreserved and stored in a biobank. Patients in treatment arm B receive intrathecal autologous MSCs. The treatment is blinded for the patients. Primary outcome is assessed at six months and secondary outcomes are assessed at six, twelve and eighteen months post baseline. Investigator assessing outcomes are blinded to patient treatment allocation.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 18
Est. completion date January 4, 2025
Est. primary completion date October 4, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Age =18 to =55, both genders 2. Diagnosis of secondary progressive or primary progressive MS using revised McDonald criteria of clinically definite MS 3. An EDSS score of 4 to 7 4. Disease duration 2 - 15 years 5. Signed, written informed consent Exclusion Criteria: 1. Any illness or prior/ongoing treatment that in the opinion of the investigators would jeopardize the ability of the patient to tolerate autologous stem cell treatment 2. Any ongoing infection, including Tbc, CMV, EBV, HSV, VZV, hepatitis virus, toxoplasmosis, HIV or syphilis infections, as well as heaptitis B surface antigen positivity and/or hepatitis C PCR positivity 3. Current immunomodulatory/immunosuppressive treatment 4. Immunomodulatory/immunosuppressive treatment within 6 months prior to inclusion. This includes, but is not restricted to treatment with natalizumab, fingolimod, dimetylfumurat, glatiramer acetate, interferon beta medications, teriflunomide, and siponimod. 5. Treatment with kladribin, ocrelizumab, rituximab, and alemtuzumab within 12 months prior to inclusion 6. Treatment with hematopoietic stem cell therapy within 12 months prior to inclusion 7. Treatment with glucocorticoids or ACTH within three months prior to start of inclusion 8. Having experienced an MS relapse within 2 years prior to study inclusion 9. Current treatment with fampridin 10. History of malignancy other than basal cell carcinoma of the skin or carcinoma in situ that has been in remission for more than one year 11. Severely limited life expectancy by another co-morbid illness 12. History of previous diagnosis of myelodysplasia or previous hematologic disease (including lymphoproliferative disease, bone marrow insufficiency or previous lymphoid irradiation) or current clinically relevant abnormalities of white blood cell counts 13. Immunocompromised patients 14. Estimated glomerular filtration rate <60 ml/min/1.73 m2 or known renal failure 15. Bleeding or clotting diathesis or the use of antithrombotic or anticoagulative treatment 16. Platelet (thrombocyte) count <100 x 10*9/L 17. Participation in another experimental clinical study within the preceding 12 months 18. Contraindications to MRI 19. Prior or current major depression 20. Prior or current psychiatric illness, mental deficiency or cognitive dysfunction influencing the patient ability to make an informed consent or comply with the treatment and follow-up phases of this protocol. 21. Pregnancy or risk of pregnancy (this includes patients that are unwilling to practice active contraception during the duration of the study), breastfeeding or lactation 22. History of autologous/allogenic bone marrow transplantation or peripheral blood cell transplant 23. Known hypersensitivity against paracetamol, codein or xylocain 24. Diagnosis or strong suspicion of polyneuropathy 25. Prior or current alcohol or drug dependencies 26. Inability to give informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
MSCs
Autologous bone-marrow derived mesenchymal stem cells
Drug:
Saline
Isotonic saline

Locations

Country Name City State
Norway Haukeland University Hospital Bergen Vestland
Norway Akershus university hospital Lørenskog Viken
Norway University hospital of North Norway Tromsø Troms Og Finnmark
Norway St.Olav university hospital Trondheim Trøndelag

Sponsors (6)

Lead Sponsor Collaborator
Haukeland University Hospital St. Olavs Hospital, University Hospital of North Norway, University Hospital Ulm, University Hospital, Akershus, University of Bergen

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Neurophysiological parameters - Combined evoked potentials Somatosensoric evoked potentials (SEP) + visual evoked potentials (VEP) + motor evoked potentials (MEP), latency (ms) and amplitude (mV) 6 months
Secondary Neurophysiological parameters - Somatosensoric evoked potantials SEP, latency (ms) and amplitude (mV) 6 and 12 months
Secondary Neurophysiological parameters - Motor evoked potentials MEP, latency (ms) and amplitude (mV) 6 and 12 months
Secondary Neurophysiological parameters - Visual evoked potentials VEP, latency (ms) and amplitude (mV) 6 and 12 months
Secondary MRI-Lesion volumes T1- and T2-weighted hyperintense lesion volume 6 and 12 months
Secondary MR- Brain volumes Brain volumes 6 and 12 months
Secondary Expanded disability status scale EDSS 6, 12 and 18 months
Secondary Patient reported outcomes (PROs) Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), European Quality of Life 5 dimensions (EQ-5D-5L), Multiple Sclerosis Impact Scale (MSIS) and Fatigue severity scale (FSS) 6, 12 and 18 months
Secondary Nine-Hole-Peg Test (9-HPT) Nine-Hole-Peg Test (9-HPT) 6, 12 and 18 months
Secondary Timed 25 Foot Walk (T25FW) Timed 25 Foot Walk (T25FW) 6, 12 and 18 months
Secondary Visual function Visual acuity, visual field, color vision and contrast sensitivity 6, 12 and 18 months
Secondary Optical coherence tomography (OCT) Retinal thickness 6, 12 and 18 months
Secondary Rate and nature of adverse- and serious adverse events Adverse events 6, 12 and 18 months
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4